Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (29)
Rajani Rai, Stanley Lightfoot & Doris Mangiaracina Benbrook. (2024) Manipulation of metabolic responses enhances SHetA2 efficacy without toxicity in cervical cancer cell lines and xenografts. Gynecologic Oncology 180, pages 44-54.
Crossref
Crossref
Rajani Rai, Vishal Chandra, Amy L. Kennedy, Rosemary E. Zuna & Doris Mangiaracina Benbrook. (2022) Distinct mechanism of cervical cancer cell death caused by the investigational new drug SHetA2. Frontiers in Oncology 12.
Crossref
Crossref
Ahmed Elwakeel. (2022) Abrogating the Interaction Between p53 and Mortalin (Grp75/HSPA9/mtHsp70) for Cancer Therapy: The Story so far. Frontiers in Cell and Developmental Biology 10.
Crossref
Crossref
Doris Mangiaracina Benbrook. (2022) SHetA2 Attack on Mortalin and Colleagues in Cancer Therapy and Prevention. Frontiers in Cell and Developmental Biology 10.
Crossref
Crossref
Rajani Rai, Amy L. Kennedy, Zitha Redempta Isingizwe, Pouya Javadian & Doris Mangiaracina Benbrook. (2021) Similarities and Differences of Hsp70, hsc70, Grp78 and Mortalin as Cancer Biomarkers and Drug Targets. Cells 10:11, pages 2996.
Crossref
Crossref
Vishal Chandra, Rajani Rai & Doris Mangiaracina Benbrook. (2021) Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer. Cancers 13:10, pages 2322.
Crossref
Crossref
Rebecca M. Harman, Sanjna P. Das, Arianna P. Bartlett, Gat Rauner, Leanne R. Donahue & Gerlinde R. Van de Walle. (2020) Beyond tradition and convention: benefits of non-traditional model organisms in cancer research. Cancer and Metastasis Reviews 40:1, pages 47-69.
Crossref
Crossref
Satish K. Ramraj, Sugantha P. Elayapillai, Richard C. Pelikan, Yan D. Zhao, Zitha R. Isingizwe, Amy L. Kennedy, Stanley A. Lightfoot & Doris M. Benbrook. (2020) Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53. International Journal of Cancer 147:4, pages 1086-1097.
Crossref
Crossref
Sanjida Mahjabeen, Manolya Kukut Hatipoglu, Stanley D. Kosanke, David Garcia-Contreras, Doris M. Benbrook & Lucila Garcia-Contreras. (2020) Vaginal Suppositories Containing SHetA2 to Treat Cervical Dysplasia: Pharmacokinetics of Daily Doses and Preliminary Safety Profile. Journal of Pharmaceutical Sciences 109:6, pages 2000-2008.
Crossref
Crossref
Amy L. Kennedy, Rajani Rai, Zitha Redempta Isingizwe, Yan Daniel Zhao, Stanley A. Lightfoot & Doris M. Benbrook. (2020) Complementary Targeting of Rb Phosphorylation and Growth in Cervical Cancer Cell Cultures and a Xenograft Mouse Model by SHetA2 and Palbociclib. Cancers 12:5, pages 1269.
Crossref
Crossref
Ankur Sharma, Mengjie Li, Elangovan Thavathiru, Mariam Ibrahim, Lucila Garcia-Contreras, Doris M Benbrook & Sukyung Woo. (2020) Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice. The AAPS Journal 22:2.
Crossref
Crossref
Krishna Kumar Gnanasekaran, Tim Pouland, Richard A. Bunce, K. Darrell Berlin, Suaad Abuskhuna, Dipendra Bhandari, Maryam Mashayekhi, Donghua H. Zhou & Doris M. Benbrook. (2020) Tetrahydroquinoline units in flexible heteroarotinoids (Flex-Hets) convey anti-cancer properties in A2780 ovarian cancer cells. Bioorganic & Medicinal Chemistry 28:1, pages 115244.
Crossref
Crossref
Emily Ginn, Jihyun Baek, Hongye Zou, Maryam M.J. Fallatah, Shengquan Liu, Mary B. Sevigny & Maggie Louie. (2019) Enantiomer of the novel flexible heteroarotinoid, SL-1-09, blocks cell cycle progression in breast cancer cells. European Journal of Pharmacology, pages 172634.
Crossref
Crossref
Manolya Kukut Hatipoglu, Sanjida Mahjabeen & Lucila Garcia-Contreras. (2019) Development and validation of a reverse phase HPLC method for SHetA2, a novel anti-cancer drug, in mouse biological samples. Journal of Pharmaceutical and Biomedical Analysis 170, pages 124-131.
Crossref
Crossref
Baskar Nammalwar, Richard A. Bunce, K. Darrell Berlin, Doris M. Benbrook & Coralee Toal. (2019) Synthesis and biological evaluation of SHetA2 (NSC-721689) analogs against the ovarian cancer cell line A2780. European Journal of Medicinal Chemistry 170, pages 16-27.
Crossref
Crossref
Hongye Zou, Mary B. Sevigny, Shengquan Liu, David T. Madden & Maggie C. Louie. (2019) Novel flexible heteroarotinoid, SL-1-39, inhibits HER2-positive breast cancer cell proliferation by promoting lysosomal degradation of HER2. Cancer Letters 443, pages 157-166.
Crossref
Crossref
Mariam Ibrahim, Manolya Kukut Hatipoglu & Lucila Garcia-Contreras. (2019) Cryogenic Fabrication of Dry Powders to Enhance the Solubility of a Promising Anticancer Drug, SHetA2, for Oral Administration. AAPS PharmSciTech 20:1.
Crossref
Crossref
Sanjida Mahjabeen, Manolya Kukut Hatipoglu, Doris M. Benbrook & Lucila Garcia-Contreras. (2018) Pharmacokinetics and Pharmacodynamics of Escalating Doses of SHetA2 After Vaginal Administration to Mice. Journal of Pharmaceutical Sciences 107:12, pages 3179-3186.
Crossref
Crossref
Field M. WattsJr.Jr., Tim Pouland, Richard A. Bunce, K. Darrell Berlin, Doris M. Benbrook, Maryam Mashayekhi, Dipendra Bhandari & Donghua Zhou. (2018) Activity of oxygen-versus sulfur-containing analogs of the Flex-Het anticancer agent SHetA2. European Journal of Medicinal Chemistry 158, pages 720-732.
Crossref
Crossref
Sanjida Mahjabeen, Manolya Kukut Hatipoglu, Doris M. Benbrook, Stanley D. Kosanke, David Garcia-Contreras & Lucila Garcia-Contreras. (2018) Influence of the estrus cycle of the mouse on the disposition of SHetA2 after vaginal administration. European Journal of Pharmaceutics and Biopharmaceutics 130, pages 272-280.
Crossref
Crossref
Doris M. Benbrook, Naveena B. Janakiram, Vishal Chandra, Gopal Pathuri, Venkateshwar Madka, Nicole C. Stratton, Chioniso P. Masamha, Cassadie N. Farnsworth, Lucila Garcia-Contreras, Manolya Kukut Hatipoglu, Stan Lighfoot & Chinthalapally V. Rao. (2017) Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. Investigational New Drugs 36:4, pages 561-570.
Crossref
Crossref
Ankur Sharma, Doris Mangiaracina Benbrook & Sukyung Woo. (2018) Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2. PLOS ONE 13:4, pages e0194046.
Crossref
Crossref
Mariam Ibrahim, Manolya Kukut Hatipoglu & Lucila Garcia-Contreras. (2017) SHetA2 Dry Powder Aerosols for Tuberculosis: Formulation, Design, and Optimization Using Quality by Design. Molecular Pharmaceutics 15:1, pages 300-313.
Crossref
Crossref
Maryam M. Fallatah, Shengquan Liu, Mary B. Sevigny, Hongye Zou & Maggie C. Louie. (2017) Novel flexible heteroarotinoid, SL-1-18, promotes ERα degradation to inhibit breast cancer cell growth. Cancer Letters 408, pages 82-91.
Crossref
Crossref
Sanjida Mahjabeen, Manolya K. Hatipoglu, Vishal Chandra, Doris M. Benbrook & Lucila Garcia-Contreras. (2017) Optimization of a Vaginal Suppository Formulation to Deliver SHetA2 as a Novel Treatment for Cervical Dysplasia. Journal of Pharmaceutical Sciences.
Crossref
Crossref
Shengquan Liu, Maggie C. Louie, Vanishree Rajagopalan, Guangyan Zhou, Esmeralda Ponce, Tran Nguyen & Linda Green. (2015) Synthesis and evaluation of the diarylthiourea analogs as novel anti-cancer agents. Bioorganic & Medicinal Chemistry Letters 25:6, pages 1301-1305.
Crossref
Crossref
Doris Mangiaracina Benbrook, Baskar Nammalwar, Andrew Long, Hiroyuki Matsumoto, Anil Singh, Richard A. Bunce & K. Darrell Berlin. (2013) SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres. Investigational New Drugs 32:3, pages 412-423.
Crossref
Crossref
Doris Mangiaracina Benbrook, Suresh Guruswamy, Yuhong Wang, Zhongjie Sun, Altaf Mohammed, Yuting Zhang, Qian Li & Chinthalapally V. Rao. (2013)
Chemoprevention of Colon and Small Intestinal Tumorigenesis in
APCmin/+
Mice By SHetA2 (NSC721689) without Toxicity
. Cancer Prevention Research 6:9, pages 908-916.
Crossref
Crossref
Mark F. Naylor, David M. Thompson, Stan Lightfoot & Doris Mangiaracina Benbrook. (2013) Anti-Cancer Activities and Interaction of Imiquimod and Flex-Het, SHetA2, in Melanoma and Ovarian Cancer. Journal of Cancer Therapy 04:06, pages 7-19.
Crossref
Crossref